Reprogramming of cancer stem cells into non-tumorigenic cells using stem cell exosomes for cancer therapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Kyoung Soo | - |
dc.contributor.author | Choi, Ji Suk | - |
dc.contributor.author | Cho, Yong Woo | - |
dc.date.accessioned | 2021-06-22T10:02:47Z | - |
dc.date.available | 2021-06-22T10:02:47Z | - |
dc.date.issued | 2019-05 | - |
dc.identifier.issn | 0006-291X | - |
dc.identifier.issn | 1090-2104 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/2937 | - |
dc.description.abstract | Cancer stem cells (CSCs) are a small population of cells with stem cell-like properties found in tumors. CSCs are closely associated with tumor heterogeneity, which influences tumor progress, metastasis, and drug resistance. Here, we propose a concept to enhance efficacy of cancer therapy through CSC reprogramming into non-tumorigenic cells using stem cell -derived exosomes with osteoinductive potential. We hypothesized that exosomes derived from osteogenic differentiating human adipose-derived stem cells (0D-EX0s) contain specific cargos capable of inducing osteogenic differentiation of CSCs. Quantitative RT-PCR analysis revealed that OD-EXO5 enhanced the expression of osteogenic-related genes, such as alkaline phosphatase (ALPL), osteocalcin (BGLAP), and runt-related transcription factor 2 (RUNX2). In addition, expression of drug-resistance genes such as ATP binding cassette (ABC) transporter, the breast cancer gene family (BCRA1 and BCRA2), and the ErbB gene family were significantly decreased in OD-EXO-treated CSCs. Our findings suggest that OD-EXOs function as a biochemical cue for CSC reprogramming and contribute to overcoming therapeutic resistance. (C) 2019 Elsevier Inc. All rights reserved. | - |
dc.format.extent | 6 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | ACADEMIC PRESS INC ELSEVIER SCIENCE | - |
dc.title | Reprogramming of cancer stem cells into non-tumorigenic cells using stem cell exosomes for cancer therapy | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1016/j.bbrc.2019.03.072 | - |
dc.identifier.scopusid | 2-s2.0-85063087084 | - |
dc.identifier.wosid | 000468258700014 | - |
dc.identifier.bibliographicCitation | BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, v.512, no.3, pp 511 - 516 | - |
dc.citation.title | BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS | - |
dc.citation.volume | 512 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 511 | - |
dc.citation.endPage | 516 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Biophysics | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Biophysics | - |
dc.subject.keywordPlus | RETINOIC ACID | - |
dc.subject.keywordPlus | DIFFERENTIATION | - |
dc.subject.keywordAuthor | Exosomes | - |
dc.subject.keywordAuthor | Cancer stem cells | - |
dc.subject.keywordAuthor | Reprogramming | - |
dc.subject.keywordAuthor | Drug resistance | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0006291X19304553?via%3Dihub | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
55 Hanyangdeahak-ro, Sangnok-gu, Ansan, Gyeonggi-do, 15588, Korea+82-31-400-4269 sweetbrain@hanyang.ac.kr
COPYRIGHT © 2021 HANYANG UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.